Endodiag products

Endodiag together with several expert gynecologists has developed EndoGram, a 10-biomarker test based on the analysis of biopsies taken during surgery. Thanks to a proprietary algorithm combining other patient clinical factors, EndoGram provides for each patient a risk of disease recurrence score and a biological profile aimed to help the physician discard unsuitable treatments. EndoGram is currently under clinical validation.

Endodiag has built a regulatory compliant biobank of more than 1000 human biological samples, including fixed biopsies, serum, plasma and peritoneal fluid samples, as well as endometriosis primary cell cultures and endometriosis derived cell lines. These samples are annotated with patients’ clinical data. EndoBiobank® together with the company’s established clinical network of international experts is an ideal tool for the assessment of new targets of interest in endometriosis and the evaluation of potential efficacy of new drug candidates. For this latter purpose Endodiag has developed a growing range of cell-based assays such as apoptosis, proliferation or migration assays.

EndoDTectis a blood test based on the analysis of a combination of biomarkers. Changes in their expression levels indicate if a subject has endometriosis or not. Combining high sensitivity and specificity, EndoDTect has the potential to dramatically reduce diagnosis delays. Endodiag is currently conducting validation studies to confirm the predictive value of EndoDTect® for disease detection.